Managing diabetic dyslipidemia: Beyond statin therapy

Current Diabetes Reports

Volumn 9, Issue 1, 2009, Pages 11-17

  Neeli, Hemanth ^a   Gadi, Ram ^b   Rader, Daniel J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FLUSHING; GLYCEMIC CONTROL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MONOTHERAPY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT;

ANTILIPEMIC AGENTS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; LIPIDS; LIPOPROTEINS, VLDL; NIACIN; PPAR ALPHA;

EID: 59749096514     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-009-0004-y     Document Type: Review

References (46)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk-factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
2. Miettinen H, Lehto S, Salomaa V, et al.: Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998, 21:69-75.
3. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
4. LaRosa JC, Grundy SM, Waters DD, et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435.
5. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
6. Laakso M, Voutilainen E, Sarlund H, et al.: Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 1985, 56:271-281.
7. Feingold KR, Grunfeld C, Pang M, et al.: LDL subclass phenotypes and triglyceride-metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992, 12:1496-1502.
8. Taskinen MR: DiabeFic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
9. Assmann G, Schulte H: The iRportance of triglycerides: results from the Prospective Cardiovascular Münster (ProcAM) Study. Eur J Epidemiol 1992, 8:99-103.
10. Haffner SM, Stern MP, Hazuda HP, et al.: Cardiovascular risk-factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263:2893-2898.
11. Rosenson RS: Statins iL atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2004, 173:1-12.
12. Taskinen MR: Pathogenesis of dyslipidemia in type 2 diabetes. Exp Clin Endocrinol Diabetes 2001, 109:S180-S188.
13. Wang CS, McConathy WJ, Kloer HU, Alaupovic P: Modulation of lipoprotein-lipase activity by apolipoproteins. Effect of apolipoprotein-C-III. J Clin Invest 1985, 75:384-390.
14. Sehayek E, Eisenberg S: Mechanisms of inhibition by apolipoprotein C of apolipoprotein-E-dependent cellular-metabolism of human triglyceride-rich lipoproteins through the low-density-lipoprotein receptor pathway. J Biol Chem 1991, 266:18259-18267.
15. Rashid S, Uffelman KD, Lewis GF: The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002, 16:24-28.
16. Braschi S, Neville TA, Maugeais C, et al.: Role of the kidney in regulating the metabolism of HDL in rabbits: Evidence that iodination alters the catabolism of apolipoprotein A-I by the kidney. Biochemistry 2000, 39:5441-5449.
17. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2589.
18. Collins R, Armitage J, Parish S, et al.: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
19. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
20. Colhoun HM, Betteridge DJ, Durrington PN: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
21. Pyorala K, Pedersen TR, Kjekshus J, et al.: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997, 20:614-620.
22. Goldberg RB, Mellies MJ, Sacks FM, et al.: Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998, 98:2513-2519.
23. Keech A, Colquhoun D, Best J, et al.: Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: Results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
24. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
25. Sacks FM, Tonkin AM, Craven T, et al.: Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002, 105:1424-1428.
26. Keating GM, OrmrodAD: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002, 62:1909-1944.
27. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
28. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
29. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005, 45:185-197.
30. Koskinen P, Manttari M, Manninen V, et al.: Coronary heart-disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992, 15:820-825.
31. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study [no authors listed]. Circulation 2000, 102:21-27.
32. Steiner G, Hamsten A, Hosking J, et al.: Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
33. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 2005, 366:1849-1861.
34. Ginsberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):56i-67i.
35. Soudijn W, van Wijngaarden I, Ijzerman AP: Nicotinic acid receptor subtypes and their ligands. Med Res Rev 2007, 27:417-433.
36. Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997, 17:2020-2028.
37. Clofibrate and niacin in coronary heart disease [no authors listed]. JAMA 1975, 231:360-381.
38. Canner PL, Berge KG, Wenger NK, et al.: 15-year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
39. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
40. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006, 22:2243-2250.
41. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106:453-458.
42. PalumEo PJ: Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998, 12:110-119.
43. Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
44. Koren MJ, Maccubbin D, Davidson M, et al.: Flushing profile of extended release niacin/laropiprant versus gradually titrated Niaspan in patients with dyslipidemia. J Am Coll Cardiol 2008, 51:A324-A325.
45. Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005, 95:1309-1313.
46. Alsheikh-Ali AA, Karas RH: Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am J Cardiol 2007, 99:379-381.